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Case report
A 59-year-old Caucasian female with a past medical his-
tory of  hypertension, type II diabetes, and uterine carci-
noma, status posthysterectomy, presented to the urologist 
with hematuria for over one year. She denied any weight 
loss or constitutional symptoms. A prior evaluation at an 
outside institution, including several cystoscopies and a CT 
scan, reportedly failed to reveal any abnormality. 
On physical exam, she had a palpable, firm, 3-4-cm mass 
on the right aspect of  the urethra. Bloody drainage was 
expressed from the urethral meatus on palpation. Cystos-
copy revealed extrinsic compression of  the urethra. 
Gadolinium-enhanced pelvic MRI revealed a 3.4 x 3.3 x 
3.9-cm infiltrative mass in the region of  the urethra. The 
mass was T2 hyperintense (Fig. 1), T1 hypointense (Fig. 2), 
and demonstrated slightly heterogeneous enhancement 
(Figs. 3 and 4). An incomplete fat plane was identified be-
tween the mass and the urinary bladder, with possible ve-
sicular invasion identified on the sagittal images (Fig. 3). No 
lymphadenopathy was detected.
The patient underwent radical cystectomy and bilateral 
pelvic lymphadenectomy. Surgical pathology revealed a 
3.6-cm, poorly differentiated, urethral adenocarcinoma, 
clear-cell variant (Figs. 5 and 6).
It was the urologist’s opinion that the tumor had origi-
nated within a urethral diverticulum, due to its location and 
the fact that the mass appeared to be encapsulated and 
without any vesicular or urethral invasion. “A diverticulum 
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Primary urethral carcinoma is a rare malignancy with an annual age-adjusted incidence rate of  1.5 per 
million in females in the U.S. The three main histologic subtypes include transitional-cell carcinoma, 
squamous-cell carcinoma, and adenocarcinoma. Of  these, adenocarcinoma is the least common. Female 
urethral carcinomas are aggressive neoplasms with a generally poor prognosis. We report a case of  the 
clear-cell variant of  adenocarcinoma.
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Figure 1. 59-year-old female with adenocarcinoma, clear-
cell variant. T2 fat-saturated MR image in the coronal plane 
demonstrates a mass (*) inferior to the urinary bladder (#).
replaced with neoplasm” was the urologist’s characteriza-
tion. This suspicion was not borne out following pathologi-
cal analysis, which showed invasion through the periure-
thral muscle and direct extension into the bladder neck.
One left and six right pelvic lymph nodes were submit-
ted, all of  which were found to be benign.
Discussion
The female urethra is an approximately 4cm-long tubu-
lar conduit lined by transitional epithelium in its proximal 
third and stratified squamous epithelium in its distal two-
thirds. Urethral carcinomas are rare neoplasms, represent-
ing less than 0.02% of  all malignancies in women and with 
an annual age-adjusted incidence rate of  1.5 per million 
females in the U.S. (1, 2). These neoplasms may present as 
exophytic, papillary, fungating masses or infiltrating tumors 
(3). Risk factors include infection with the human papil-
loma virus and urethral diverticula (1). These malignancies 
typically affect postmenopausal patients, whose symptoms 
may include a mass, dyspareunia, dysuria, hematuria, or 
partial obstruction (4). 
Imaging can be extremely helpful in the workup of  
women presenting with urethral symptoms, as the clinical 
assessment is often difficult. High-resolution multiplanar 
magnetic resonance (MR) imaging with phased-array pelvic 
and endovaginal coils demonstrates the urethral anatomy in 
detail and provides an accurate road map for surgeons (3). 
However, imaging features cannot distinguish between his-
tologic subtypes, and histopathologic analysis is required for 
definitive diagnosis. 
Tumor histology depends on the site of  origin within the 
urethra. Transitional-cell carcinoma occurs more com-
monly in the proximal one-third. Squamous-cell carcinoma 
and adenocarcinoma are more common in the distal two-
thirds. Squamous-cell carcinoma is the most common sub-
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Figure 2. 59-year-old female with adenocarcinoma, clear-
cell variant. T1-weighted MR image in the sagittal plane 
demonstrates a low-signal 3.9-cm mass (*) inferior to the 
urinary bladder (#).
Figure 3. 59-year-old female with adenocarcinoma, clear-
cell variant. T1 fat-saturated postcontrast MR image in the 
sagittal plane demonstrates heterogeneous enhancement 
of the periurethral mass (*) with possible vesicular invasion 
(arrow).
Figure 4. 59-year-old female with adenocarcinoma, clear-
cell variant. Axial, T1 fat-saturated postcontrast MR image 
demonstrates heterogeneous enhancement of the infiltra-
tive periurethral mass (*).
type overall; however, adenocarcinoma is the most common 
type to arise from diverticula (1).
Adenocarcinomas account for approximately 10% of  
female urethral carcinomas, and clear-cell variant repre-
sents approximately 40% of  these cases. Amin et al report 
that approximately 56 cases of  this rare malignancy have 
been reported in women, and three cases have been re-
ported in men (1). Histologically, clear-cell carcinoma dis-
plays tubulocystic, tubular, papillary, or diffuse patterns, 
frequently in combination. The cytoplasm is usually mod-
erate to abundant and varies from clear to eosinophilic (1). 
At imaging, adenocarcinoma typically appears as an 
exophytic, heterogeneously enhancing tumor. On T2 MRI, 
these tumors show high T2 signal with a low-intensity pe-
ripheral rim and variable contrast enhancement, findings 
that were demonstrated on this case (4). 
Unfortunately, carcinoma of  the female urethra carries a 
poor prognosis. Up to 50% of  women present with meta-
static disease (1). Prognostic factors include tumor location 
(proximal, distal, or entire), depth of  invasion of  the ure-
thral wall, and size of  the tumor. In DiMarco’s series of  
patients at the Mayo Clinic, pathologic stage and positive 
lymph nodes were predictors of  recurrence and cancer-
specific survival (5).
Surgical resection is the treatment of  choice. Urologists 
classify female urethral tumors as either “anterior” or “pos-
terior or entire,” as this system has significant prognostic 
value. Anterior tumors are limited to the meatus or distal 
one-third, and posterior or entire tumors involve the 
proximal two-thirds or the entire urethra (1, 4). The neo-
plasm that we present affected the patient’s entire urethra. 
Overall survival rates are approximately 50% for anterior 
tumors and 6% for entire tumors (1). Due to the rarity of  
these neoplasms, more data on radiotherapy is needed (6). 
Indications are that disease specific survival may be im-
proved with a multimodality approach that uses surgery 
and adjuvant concurrent chemoradiotherapy (4, 6).
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Figure 5. 59-year-old female with adenocarcinoma, clear-
cell variant. H&E stained photomicrograph at 40x magnifi-
cation demonstrates clear-cell adenocarcinoma in a tubular 
pattern. Note the clear cytoplasm.
Figure 6. 59-year-old female with adenocarcinoma, clear-
cell variant. At 60x magnification, hobnail cells with nuclear 
hyperchromasia, pleomorphism, and nucleoli are visible 
(green arrowheads).
